PONTE
VEDRA, Fla., Jan. 24,
2024 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., (Nasdaq: CVKD), a biopharmaceutical company developing
tecarfarin, a late-stage novel oral and reversible anticoagulant
(blood thinner) designed to prevent heart attacks, strokes and
deaths due to blood clots in patients with certain conditions,
announced today that Douglas
Losordo, M.D., Chief Medical Officer of Cadrenal, will
participate in a fireside chat moderated by Joe Pantginis, Ph.D., Managing Director of
Research at H.C. Wainwright & Co., at the Lytham Partners 2024
Investor Select Conference. Management will also host one-on-one
meetings with investors.
Company Webcast
The webcasted fireside chat will take
place at 11:00 am ET on Thursday, February
1, 2024. The webcast can be accessed at
https://wsw.com/webcast/lytham10/cvkd/2081408 or on the
Company's website at https://www.cadrenal.com/investors/. The
webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in
virtual one-on-one meetings throughout the event. To arrange a
meeting with management, please contact Lytham Partners at
1x1@lythampartners.com or register for the event at
https://lythampartners.com/select2024invreg/.
Further information on the conference is available at
https://lythampartners.com/select2024.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin, a late-stage novel oral and
reversible anticoagulant (blood thinner), to prevent heart attacks,
strokes, and deaths due to blood clots in patients with certain
conditions. Tecarfarin has orphan drug and fast track designations
for the prevention of systemic thromboembolism (blood clots) of
cardiac origin in patients with end stage kidney disease (ESKD) and
atrial fibrillation (AFib). Tecarfarin is specifically designed to
leverage a different metabolism pathway than the oldest and most
commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has
been evaluated in eleven (11) human clinical trials and more than
1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated in both
healthy adult subjects and patients with chronic kidney disease.
For more information, please visit:
www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-a-fireside-chat-at-the-lytham-partners-2024-investor-select-conference-on-february-1-2024-302042716.html
SOURCE Cadrenal Therapeutics, Inc.